精選課程
內科用藥
When can we decline the use of anthracycline in HER2 positive early breast cancer?
積分登錄期間
2021/12/17 17:00 - 2022/01/18 00:00
積分登錄已結束
課程開放閱讀期間
2021/12/17 17:00 - 2023/12/18 00:00
認證積分
專業 1.0
課程開放對象
醫師會員、部分公司會員、網路會員、指定名單
課程介紹
The management of HER2 positive breast cancer has rapidly evolved over the last 20 years. TRYPHAENA and TRAIN2 studies show the potential to omit anthracycline in the setting of dual HER2 blockade. The lecture will discuss the strategy of escalate and de-escalate treatment with less chemotherapy for early stage HER2 positive breast cancer.